Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
ingenol mebutate (Picato®)
Reference No. 1392
Publication date:
31/07/2013
Last review date:
30/08/2016
Appraisal information
ingenol mebutate (Picato®) 150 micrograms/g gel
ingenol mebutate (Picato®) 500 micrograms/g gel
Company:
LEO Laboratories Ltd
BNF category:
Skin
NMG meeting date:
10/04/2013
AWMSG meeting date:
08/05/2013
Submission Type:
Full Submission
Status:
Recommended
Advice No:
1013
Ratification by Welsh Government:
29/07/2013
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Ingenol mebutate (Picato®) is recommended as an option for use within NHS Wales for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (AK) in adults.
Final Appraisal Recommendation (FAR)
Download
ingenol mebutate (Picato) 1392 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
ingenol mebutate (Picato) 1392 ASAR
Clinical Expert (CE) Summary
Download
ingenol mebutate (Picato) 1392 CE summary